[go: up one dir, main page]

NL194429C - Waterhoudende ranitidinepreparaten. - Google Patents

Waterhoudende ranitidinepreparaten. Download PDF

Info

Publication number
NL194429C
NL194429C NL8401524A NL8401524A NL194429C NL 194429 C NL194429 C NL 194429C NL 8401524 A NL8401524 A NL 8401524A NL 8401524 A NL8401524 A NL 8401524A NL 194429 C NL194429 C NL 194429C
Authority
NL
Netherlands
Prior art keywords
ranitidine
solution
composition
aqueous
range
Prior art date
Application number
NL8401524A
Other languages
English (en)
Dutch (nl)
Other versions
NL8401524A (nl
NL194429B (nl
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10542680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL194429(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NL8401524A publication Critical patent/NL8401524A/nl
Publication of NL194429B publication Critical patent/NL194429B/xx
Application granted granted Critical
Publication of NL194429C publication Critical patent/NL194429C/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
NL8401524A 1983-05-13 1984-05-11 Waterhoudende ranitidinepreparaten. NL194429C (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB838313217A GB8313217D0 (en) 1983-05-13 1983-05-13 Pharmaceutical compositions
GB8313217 1983-05-13

Publications (3)

Publication Number Publication Date
NL8401524A NL8401524A (nl) 1984-12-03
NL194429B NL194429B (nl) 2001-12-03
NL194429C true NL194429C (nl) 2002-04-04

Family

ID=10542680

Family Applications (1)

Application Number Title Priority Date Filing Date
NL8401524A NL194429C (nl) 1983-05-13 1984-05-11 Waterhoudende ranitidinepreparaten.

Country Status (20)

Country Link
US (1) US4585790A (it)
JP (1) JPH0639378B2 (it)
AU (1) AU568647B2 (it)
BE (1) BE899635A (it)
CA (1) CA1216240A (it)
CH (1) CH662272A5 (it)
CZ (1) CZ281598B6 (it)
DE (1) DE3417606C2 (it)
DK (1) DK165663B (it)
FR (1) FR2547727B1 (it)
GB (2) GB8313217D0 (it)
IE (1) IE57397B1 (it)
IL (1) IL71813A (it)
IT (1) IT1179367B (it)
NL (1) NL194429C (it)
NZ (1) NZ208127A (it)
PH (1) PH20574A (it)
SE (1) SE459898B (it)
SK (1) SK279526B6 (it)
ZA (1) ZA843584B (it)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8629781D0 (en) * 1986-12-12 1987-01-21 Glaxo Group Ltd Pharmaceutical compositions
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorbate comprising ranitidine together with a synthetic cation exchange resin, its preparation and pharmaceutical compositions containing it
US5219563A (en) * 1988-05-11 1993-06-15 Glaxo Group Limited Drug adsorbates
FR2633181B1 (fr) * 1988-06-24 1992-01-10 Glaxo Lab Sa Composition pharmaceutique a base de ranitidine et son procede de preparation
GB8927503D0 (en) * 1989-12-04 1990-02-07 Kronem Systems Inc Enzyme-amplified lanthanide chelate luminescence
US5169864A (en) * 1991-11-15 1992-12-08 Baxter International Inc. Unbuffered premixed ranitidine formulation
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
WO1995010274A1 (en) * 1993-10-14 1995-04-20 F.H. Faulding & Co. Limited Aqueous pharmaceutical composition
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
IL112779A (en) * 1994-03-01 1999-11-30 Gergely Gerhard Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
US5650421A (en) * 1995-03-31 1997-07-22 Baxter International Inc. Premixed famotidine formulation
US5976578A (en) * 1996-10-10 1999-11-02 Mcneil-Ppc, Inc. Liquid antacid compositions
US5728401A (en) * 1997-04-16 1998-03-17 Ranbaxy Laboratories, Ltd. Effervescent ranitidine formulations
GB9715423D0 (en) * 1997-07-23 1997-09-24 Glaxo Group Ltd Aqueous compositions
US7303768B2 (en) 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US20070072828A1 (en) * 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
AU3668501A (en) * 2000-02-04 2001-08-14 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
KR100412290B1 (ko) * 2001-11-27 2003-12-31 주식회사 동구제약 라니티딘 함유 현탁제 조성물 및 그의 제조방법
AU2002360025A1 (en) * 2001-12-27 2003-07-15 Terumo Kabushiki Kaisha Famotidine injection
JP2006008696A (ja) * 2003-03-20 2006-01-12 Mitsubishi Pharma Corp アルギニンアミド類を含有する医薬製剤
US7145125B2 (en) * 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
CA2577268A1 (en) * 2004-08-30 2006-03-09 Seo Hong Yoo Neuroprotective effect of solubilized udca in focal ischemic model
ATE506955T1 (de) * 2004-10-15 2011-05-15 Seo Hong Yoo Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin
WO2006050165A2 (en) * 2004-11-01 2006-05-11 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
US20060100271A1 (en) * 2004-11-08 2006-05-11 Keith Whitehead Stabilized aqueous ranitidine compositions
JP2006271748A (ja) * 2005-03-30 2006-10-12 Taiyo Yakuhin Kogyo Kk 変質しない注射剤包装
WO2007022105A2 (en) * 2005-08-12 2007-02-22 Rubicon Research Pvt. Ltd. Stable pharmaceutical compositions, processes for making the same, and methods of their use
WO2008039792A1 (en) * 2006-09-25 2008-04-03 Scidose Llc Stable pharmaceutical compositions of preserved formulation of ranitidine, process for making the same, and methods of their use
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
EP2825159B1 (en) 2012-03-15 2022-06-22 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
SI3865120T1 (sl) 2013-07-19 2025-12-31 Boehringer Ingelheim Vetmedica Gmbh Konzervirani eterificirani derivati ciklodekstrina, ki vsebujejo tekoč vodni farmacevtski sestavek
BR112016011111B1 (pt) 2013-12-04 2022-11-16 Boehringer Ingelheim Vetmedica Gmbh Composições farmacêuticas aprimoradas de pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3626054A (en) * 1967-10-25 1971-12-07 Bard Hamilton Co Inc Lupus erythematosus skin test
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
US4203909A (en) * 1978-09-26 1980-05-20 Bristol-Myers Company Furan compounds
DE3108753A1 (de) * 1981-03-07 1982-09-16 Degussa Ag, 6000 Frankfurt Neue substituierte alkyl-phenylsulfonylguanidine miteinem heterocyclischen rest

Also Published As

Publication number Publication date
CA1216240A (en) 1987-01-06
IL71813A (en) 1988-03-31
IE841179L (en) 1984-11-13
GB2142820A (en) 1985-01-30
SE8402560D0 (sv) 1984-05-11
DK165663B (da) 1993-01-04
DK237884A (da) 1984-11-14
DE3417606A1 (de) 1984-11-15
CH662272A5 (fr) 1987-09-30
NL8401524A (nl) 1984-12-03
DE3417606C2 (de) 1996-03-14
GB8313217D0 (en) 1983-06-22
IL71813A0 (en) 1984-09-30
AU568647B2 (en) 1988-01-07
IT8448182A0 (it) 1984-05-11
US4585790A (en) 1986-04-29
IT1179367B (it) 1987-09-16
NL194429B (nl) 2001-12-03
BE899635A (fr) 1984-11-12
SE459898B (sv) 1989-08-21
IT8448182A1 (it) 1985-11-11
IE57397B1 (en) 1992-08-26
CS403691A3 (en) 1992-08-12
PH20574A (en) 1987-02-18
CZ281598B6 (cs) 1996-11-13
GB2142820B (en) 1987-01-14
ZA843584B (en) 1985-12-24
FR2547727B1 (fr) 1988-02-26
GB8412108D0 (en) 1984-06-20
DK237884D0 (da) 1984-05-11
SE8402560L (sv) 1984-11-14
SK279526B6 (sk) 1998-12-02
NZ208127A (en) 1987-05-29
JPH0639378B2 (ja) 1994-05-25
AU2792984A (en) 1984-11-15
FR2547727A1 (fr) 1984-12-28
JPS59219225A (ja) 1984-12-10

Similar Documents

Publication Publication Date Title
NL194429C (nl) Waterhoudende ranitidinepreparaten.
CA2138853A1 (en) Highly concentrated immunoglobulin preparation and method for its production
US20020147239A1 (en) Esmolol formulation
US20250345386A1 (en) Micafungin compositions
NL194431C (nl) Farmaceutische preparaten die ranitidine bevatten.
EA033988B1 (ru) Инъецируемые фармацевтические композиции лефамулина
JP3720262B2 (ja) 安定化したカルベジロール注射溶液
US20060094787A1 (en) Pharmaceutical composition comprising 5-methyl-2-2'(chloro-6'-fluoroanilino) phenylacetic acid
JPH11302197A (ja) ヒアルロン酸安定化組成物
EP0682522B1 (en) Process to prepare pharmaceutical compositions containing vecuronium bromide
JPH0317094A (ja) レベカマイシン類似体の安定な溶液およびその製造
US20080095786A9 (en) Compositions And Methods For Preventing And Treating Endotoxin-Related Diseases And Conditions
US6818662B2 (en) Pharmaceutical composition
JPWO2002017932A1 (ja) Ｏｃｔ製剤
JP2022085199A (ja) ロクロニウム製剤
JP2946015B2 (ja) 安定な抗ウィルス点滴用注射剤
NL8803126A (nl) Waterige preparaten die een piperidinylcyclopentylhepteenzuurderivaat bevatten.
KR20250070034A (ko) 오렐라닌 제제
JP2019523292A (ja) 安定なイブプロフェン注射製剤用組成物
AU2004267877A1 (en) Acid containing oxaliplatin formulations
EP2976063A1 (en) Parenteral formulation of fluoroquinolone antibacterial agent and method for preparation thereof

Legal Events

Date Code Title Description
A85 Still pending on 85-01-01
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
V4 Discontinued because of reaching the maximum lifetime of a patent

Effective date: 20040511